Bayer

This study tests a new drug, 225Ac-PSMA-Trillium, in people with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug delivers radiation directly to cancer cells to damage them. The main goals are to check safety, find the best dose, and se…

This study tests an experimental drug called BAY 3401016 in 60 adults aged 18 to 45 with Alport syndrome, a rare genetic condition that leads to kidney failure. The drug blocks a protein thought to cause kidney damage, aiming to reduce protein in the urine and slow the loss of ki…

This study tests a medicine called finerenone in children aged 6 months to 18 years who have heart failure with a weak left heart pump. The medicine aims to reduce heart stress and improve function. About 111 children will receive either finerenone or a placebo for 3 months, alon…

This early-stage study tests a new medicine called BAY 3389934 in up to 36 adults with sepsis who have blood clotting issues. The goal is to find a safe dose and see how the drug affects the body. Participants are in the ICU and will be monitored for about 28 days.

This study looks at the long-term safety of adding finerenone to standard blood pressure medicines for children aged 1 to 18 with chronic kidney disease and protein in their urine. About 100 participants who were in a previous finerenone study will take the drug for up to 18 mont…

This study tests whether adding finerenone to standard blood pressure medicines can reduce protein in the urine of children with chronic kidney disease. About 219 children aged 6 months to under 18 years will take either finerenone or a placebo for 6 months. The goal is to see if…

This study follows 100 adults and children with advanced or recurrent TRK fusion cancer who are taking larotrectinib as part of their routine care. Researchers will collect information from medical records and interviews to learn about the drug's safety and how well it controls t…

This early-phase study tests a new drug, BAY 3498264, combined with the approved targeted therapy sotorasib in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see if the combination can delay or overcome resistance. A…

This study monitors the safety and effectiveness of Verquvo in 1,350 Korean adults with chronic heart failure with reduced ejection fraction. Participants take Verquvo as prescribed by their doctor, and researchers collect data on side effects, hospital stays, and deaths over up …

This study observes 300 people with Parkinson's disease who still have movement problems despite taking standard medications. Researchers will collect data on symptoms, treatments, and daily challenges over up to 5 years. The goal is to better understand how the disease changes o…

This study will analyze health data from up to 50,000 people in Germany to find out how common three eye diseases—nAMD, DME, and RVO—are and how they have changed from 2009 to 2024. Researchers will look at two large sets of health records to see how many new cases occur each yea…

This study looks at the safety of finerenone, a drug already approved for chronic heart failure, in 300 adults in South Korea. Participants take the drug as prescribed by their doctor, and researchers collect data from routine care for one year. The goal is to see how safe and ef…

This study follows about 20 Korean people aged 12 and older with hemophilia A who are already taking Jivi as prescribed by their doctor. Researchers will collect information from routine clinic visits to see how safe the drug is in real-world use. No extra tests or visits are req…

This study looks at why some people develop kidney problems after heart surgery. Researchers will collect blood and urine samples from 200 adults before and after their scheduled heart surgery to measure certain biological markers. Participants receive no experimental treatment—o…